Lipid metabolism disorders are one of the leading risk factors for the development of atherosclerotic cardiovascular diseases and remain of high importance worldwide. Despite substantial advances in reducing low-density lipoprotein (LDL) cholesterol, many patients still have a residual cardiovascular risk associated with triglyceride-rich lipoproteins, remnant cholesterol, and Lp (a). This review summarizes current information on lipid metabolism, including exogenous and endogenous lipoprotein transport pathways, as well as modern strategies for lipid-lowering therapy, in particular drugs agents targeting PCSK9, ANGPTL3, ApoC III and LP(a). Special attention is paid to promising technologies based on small interfering RNAs, antisense oligonucleotides, and CRISP/Cas9 genomic editing. The collected data indicate that an deeper understanding of the mechanisms of lipid metabolism contributes to the development of innovative treatment methods that can more effectively control dyslipidemia and reduce the risk of cardiovascular complications.
| Mualliflar | Yakhyoeva, Malika, Alieva, Rano, Shek, Aleksandr, Яхъёева, М, Алиева, Р, Шек, А, Yaxyoeva, Malika, Alieva, Rano, Shek, Aleksandr |
|---|---|
| Jurnal | O‘zbekiston кardiologiyasi |
| Nashr sanasi | 2026-03-30 |
| Jild | 3 |
| Son | 1 |
| Betlar | 75-91 |
| Til | Rus |
| DOI | 10.70626/cardiouz-2026-3-00080 |
DOI: 10.70626/cardiouz-2026-3-00080 · Maqolaning asl sahifasi
lipid metabolism, atherosclerosis, residual cardiovascular risk, LDL cholesterol, TG, TG-rich lipoproteins, LP(a), lipidlowering therapy, липидный обмен, атеросклероз, остаточный сердечно-сосудистый риск, ХС ЛПНП, ТГ, ТГ-содержащие липопротеины, ЛП (а), гиполипидемическая терапия, lipid almashinuvi, ateroskleroz, qoldiq yurak-qon tomir xavfi, past zichlikdagi lipoproteinlar xolesterini, TG, triglitseridlarga boy lipoproteinlar, LP(a), gipolipidemik terapiya
Sudden cardiac death (SCD) in young individuals is a significant medical and social problem, a substantial proportion of which is caused by inherited disorders of myocardial electrical activity. The aim of this review…
Cardiorenometabolic syndrome (CRMS) is a multifactorial clinical condition reflecting complex and interrelated pathobiological processes involving the cardiovascular, renal, and metabolic systems. Its central mechanisms…
Aim. To determine the extent of quality-of-life (KCCQ-12) recovery over 6 months of treatment in patients with ischemic cardiomyopathy (ICM), its association with the completeness of coronary revascularization, and the…
Chronic coronary syndrome (CCS) remains one of the leading causes of mortality and disability worldwide, particularly in Central Asian countries and the Republic of Uzbekistan. This review presents a contemporary…
Obstructive sleep apnea syndrome (OSAS) and ischemic heart disease (IHD) frequently coexist as comorbid conditions that mutually exacerbate one another. The aim of this review is to evaluate the impact of OSAS on…
Non-obstructive angina and ischemia of the coronary arteries (ANOCA/INOCA) is a condition in which there are signs of angina and/or ischemia in the absence of significant obstruction of the coronary arteries. This…
Cardiorenometabolic syndrome (CRMS) is one of the most important challenges in modern medicine and is considered a leading cause of morbidity and mortality worldwide. Major randomized clinical trials conducted over the…
Patient registries following acute myocardial infarction (AMI) and stroke are a key tool for quality control, real-world clinical practice research, and secondary prevention management. This article examines…
Aim: To evaluate the effect of combined antihypertensive therapy on arterial blood pressure parameters in pregnant women with uncontrolled gestational arterial hypertension. Materials and methods: The study included 60…
Aim. To determine the association between polymorphisms of the PITX2 (rs6817105) and KCNN3 (rs13376333) genes and the development of atrial fibrillation (AF) in patients with arterial hypertension (AH) in the Uzbek…